Mind the (Vote) Gap: Can We Get More STEM Students to the Polls?
An "I Voted" sticker.
This article is part of the magazine, "The Future of Science In America: The Election Issue," co-published by LeapsMag, the Aspen Institute Science & Society Program, and GOOD.
By the numbers, American college students who major in STEM disciplines—science, technology, engineering, and math—aren't big on voting. In fact, recent research suggests they're the least likely group of students to head to the ballot box, even as American political leaders cast doubt on the very kinds of expertise those students are developing on campus.
Worried educators say it's time for a rethink of STEM education at the college level. Armed with success stories and model courses, educators are pushing for colleagues to add relevance to STEM education—and instill a sense of civic duty—by bringing the outside world in.
"It's a matter of what's in the curriculum, how faculty spend their time. There are opportunities to weave [policy] within the curriculum," said Nancy L. Thomas, director of Tufts University's Institute for Democracy & Higher Education.
The most recent student voting numbers come from the 2018 mid-term election, when a national Democratic wave brought voters to the polls. Just over a third of STEM college students surveyed said they voted, the lowest percentage of six subject areas, according to a report from the institute at Tufts. Students in the education, social sciences, and humanities fields had the highest voting rates at 47%, 41%, and 39%, respectively.
Students across the board were much less engaged in the mid-year election of 2014, when just 28% of education students surveyed said they voted. STEM students again stood at the rear, with just 16% voting.
(The report analyzed whether more than 10 million college students at 1,031 U.S. institutions voted in 2014 and 2018. At the request of this magazine, the institute at Tufts removed non-U.S. resident students—who can't vote—from the findings to see if the results changed. Voting rates among STEM students remained among the lowest.)
Why aren't STEM students engaged in politics? "I have no reason to think that science students don't care about public policy issues," Tufts University's Thomas said. Instead, she believes that colleges fail to inspire STEM students to think beyond lectures and homework.
Enter the SENCER project—Science Education for New Civic Engagements and Responsibilities. Since 2001, the project has taught thousands of educators and students how to connect science and citizenship.
The roots of the project go back to 1990, when Rutgers University microbiologist Monica Devanas was assigned to teach a general-education class called "Biomedical Issues of AIDS." She decided to expand the curriculum to encompass insights about a wide range of societal issues. Guest speakers from the community, including a man with a grim diagnosis, talked about the disease and its spread. And Devanas's colleagues in a wide variety of disciplines offered course sections about AIDS and its role in areas such as literature, prisons and law.
"I always tried to make a connection, hoping to create scientifically engaged citizens by explaining the science to them in ways that they could understand."
When she first taught the class, 450 students signed up instead of the expected 100. Devanas, who'd only ever taught a few dozen students with a blackboard, suddenly had to figure out how to teach hundreds at once with the standard technology of the time: an overhead projector.
Devanas, who taught the hugely popular class for the next 18 years, said the course worked because it linked the AIDS epidemic, a hot topic at the time, to the outer world beyond immune cells and test tubes. "You really need to make it very personal and relevant. When you talk about treatment for AIDS or the cost of drugs: Who pays for this?" she said. "I always tried to make a connection, hoping to create scientifically engaged citizens by explaining the science to them in ways that they could understand."
How can other educators learn to create compelling courses? The SENCER website offers dozens of model classes for college and K–12 educators, all with the aim of making STEM classes relevant. An engineering course, for example, could expand a discussion about the nuts and bolts of automated vehicles into a conversation about whether the cars are a good idea in the first place, said Eliza J. Reilly, executive director of the National Center for Science and Civic Engagement, where SENCER is based.
SENCER, which is government-funded, holds regular conferences and has conducted research that supports the effectiveness of its programs. "This is an educational and intellectual project rather than a get-out-the-vote project. It's not intended to create activists. Instead, it's intended to help students understand that they have power as citizens," Reilly said.
What about long-term change? Will inspiring college students to engage with politics turn them into lifetime voters? Reilly said she's not aware of any research into whether STEM students continue to vote at lower levels after they graduate. That means there's no way to know if limited civic engagement in college translates to lifelong apathy. We also don't know if lower voting rates in college may help explain why few people with STEM backgrounds run for higher office.
There's another big unknown: If more people with STEM degrees vote, will they actually support fact-based policies and candidates who listen to science? The answer is not as obvious as it may appear. At Rutgers, professor Devanas pointed to the research of Yale University law/psychology professor Dan Kahan, who found that the most scientifically literate people in the U.S. also happen to be among those most polarized over climate change. In other words, a scientific mind may not necessarily translate to a pro-science vote.
Regardless of the ultimate choices that STEM students make at the ballot box, advocates will keep encouraging educators to connect science to the world beyond the classroom. As Tufts University's Thomas explained, "it just takes a lot of creativity and will."
[Editor's Note: To read other articles in this special magazine issue, visit the beautifully designed e-reader version.]
In this week's Friday Five, research on a "smart" bandage for wounds, a breakthrough in fighting inflammation, the pros and cons of a new drug for Alzheimer's, benefits of the Mediterranean diet with a twist, and we've learned to recycle a plastic that was un-recyclable.
The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.
Listen on Apple | Listen on Spotify | Listen on Stitcher | Listen on Amazon | Listen on Google
Here are the promising studies covered in this week's Friday Five:
- Research on a "smart" bandage for wounds
- A breakthrough in fighting inflammation
- The pros and cons of a new drug for Alzheimer's
- Benefits of the Mediterranean diet - with a twist
- How to recycle a plastic that was un-recyclable
Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.
Sexually Transmitted Infections are on the rise. This drug could stop them.
Cases of gonorrhea, chlamydia and syphilis soared last year, but researchers are finding that a drug known as doxy seems to reduce the number of infections.
Sexually transmitted infections (STIs) are surging across the U.S. to 2.5 million cases in 2021 according to preliminary data from the CDC. A new prevention and treatment strategy now in clinical trials may provide a way to get a handle on them.
It's easy to overlook the soaring rates of gonorrhea, chlamydia, and syphilis because most of those infections have few or no symptoms and can be identified only through testing. But left untreated, they can lead to serious damage to nerves and tissue, resulting in infertility, blindness, and dementia. Infants developing in utero are particularly vulnerable.
Covid-19 played havoc with regular medical treatment and preventive care for many health problems, including STIs. After formal lockdowns ended, many people gradually became more socially engaged, with increases in sexual activity, and may have prioritized these activities over getting back in touch with their doctors.
A second blow to controlling STIs is that family planning clinics are closing left and right because of the Dobbs decision and legislation in many states that curtailed access to an abortion. Discussion has focused on abortion, but those same clinics also play a vital role in the diagnosis and treatment of STIs.
Routine public health is the neglected stepchild of medicine. It is called upon in times of crisis but as that crisis resolves, funding dries up. Labs have atrophied and personnel have been redirected to Covid, “so access to routine screening for STIs has been decimated,” says Jennifer Mahn, director of sexual and clinical health with the National Coalition of STD Directors.
A preview of what we likely are facing comes from Iowa. In 2017, the state legislature restricted funding to family health clinics in four counties, which closed their doors. A year later the statewide rate of gonorrhea skyrocketed from 83 to 153.7 cases per 100,000 people. “Iowa counties with clinic closures had a significantly larger increase,” according to a study published in JAMA. That scenario likely is playing out in countless other regions where access to sexual health care is shrinking; it will be many months before we have the data to know for sure.
A decades-old antibiotic finds a new purpose
Using drugs to protect against HIV, either as post exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP), has proven to be quite successful. Researchers wondered if the same approach might be applied to other STIs. They focused on doxycycline, or doxy for short. One of the most commonly prescribed antibiotics in the U.S., it’s a member of the tetracycline family that has been on the market since 1967. It is so safe that it’s used to treat acne.
Two small studies using doxy suggested that it could work to prevent STIs. A handful of clinical trials by different researchers and funding sources set out to generate the additional evidence needed to prove their hypothesis and change the standard of care.
Senior researcher Victor Omollo, with the Kenya Medical Research Institute, noted, “These are prevention interventions that women can control on their own without having to seek or get consent from another person,” as is the case with condom use.
The first with results is the DoxyPEP study, conducted at two sexual health clinics in San Francisco and Seattle. It drew from a mix of transgender women and men who have sex with men, who had at least one diagnosed STI over the last year. The researchers divided the participants into two groups: one with people who were already HIV-positive and engaged in care, while the other group consisted of people who were on PrEP to prevent infection with HIV. For the active part of the study, a subset of the participants received doxy, and the rest of the participants did not.
The researchers intentionally chose to do the study in a population at the highest risk of having STIs, who were very health oriented, and “who were getting screened every three months or so as part of their PrEP program or their HIV care program,” says Connie Celum, a senior researcher at the University of Washington on the study.
Each member of the active group was given a supply of doxy and asked to take two pills within 72 hours of having sex where a condom was not used. The study was supposed to run for two years but, in May, it stopped halfway through, when a safety monitoring board looked at the data and recommended that it would be unethical to continue depriving the control group of the drug’s benefits.
Celum presented these preliminary results from the DoxyPEP study in July at the International AIDS Conference in Montreal. “We saw about a 56 percent reduction in gonorrhea, about 80 percent reduction in chlamydia and syphilis, so very significant reductions, and this is on a per quarter basis,” she told a later webinar.
In Kenya, another study is following a group of cisgender women who are taking the same two-pill regimen to prevent HIV, and the data from this research should become available in 2023. Senior researcher Victor Omollo, with the Kenya Medical Research Institute, noted that “these are prevention interventions that women can control on their own without having to seek or get consent from another person,” as is the case with condom use, another effective prevention tool.
Antibiotic resistance
Antibiotic resistance is a potentially big concern. About 25 percent of gonorrhea strains circulating in the U.S. are resistant to the tetracycline class of drugs, including doxy; rates are higher elsewhere. But resistance often is a matter of degree and can be overcome with a larger or longer dose of the drug, or perhaps with a switch to another drug or a two-drug combination.
Research has shown that an established bacterial infection is more difficult to treat because it is part of a biofilm, which can leave only a small portion or perhaps none of the cell surface exposed to a drug. But a new infection, even one where the bacteria is resistant to a drug, might still be vulnerable to that drug if it's used before the bacterial biofilm can be established. Preliminary data suggests that may be the case with doxyPEP and drug resistant gonorrhea; some but not all new drug resistant infections might be thwarted if they’re treated early enough.
“There are some tradeoffs” to these interventions, Celum says, and people may disagree on the cost of increased resistance balanced against the benefits of treating the STIs and reducing their spread within the community.
Resistance does not seem to be an issue yet for chlamydia and syphilis even though doxy has been a recommended treatment for decades, but a remaining question is whether broader use of doxy will directly worsen antibiotic resistance in gonorrhea, or promote it in other STIs. And how will it affect the gut microbiome?
In addition, Celum notes that we need to understand whether doxy will generate mutations in other bacteria that might contribute to drug resistance for gonorrhea, chlamydia or syphilis. The studies underway aim to provide data to answer these questions.
“There are some tradeoffs” to these interventions, Celum says, and people may disagree on the cost of increased resistance balanced against the benefits of treating the STIs and reducing their spread within the community. That might affect doctors' willingness to prescribe the drug.
Turning research into action
The CDC makes policy recommendations for prevention services such as taking doxy, requiring some and leaving others optional. Celum says the CDC will be reviewing information from her trial at a meeting in December, but probably will wait until that study is published before making recommendations, likely in 2023. The San Francisco Department of Public Health issued its own guidance on October 20th and anecdotally, some doctors around the country are beginning to issue prescriptions for doxy to select patients.
About half of new STIs occur in young people ages 15 to 24, a group that is least likely to regularly see a doctor. And sexual health remains a great taboo for many people who don't want such information on their health record for prying parents, employers or neighbors to find out.
“People will go out of their way and travel extensive distances just to avoid that,” says Mahn, the National Coalition director. “People identify locations where they feel safe, where they feel welcome, where they don't feel judged,” Mahn explains, such as community and family planning clinics. They understand those issues and have fees that vary depending on a person’s ability to pay.
Given that these clinics already are understaffed and underfunded, they will be hard pressed to expand services covering the labor intensive testing and monitoring of a doxyPEP regimen. Sexual health clinics don't even have a separate line item in the federal budget for health. That is something the National Association of STI Directors is pushing for in D.C.
DoxyPEP isn't a panacea, and it isn't for everyone. “We really want to try to reach that population who is most likely going to have an STI in the next year,” says Celum, “Because that's where you are going to have the biggest impact.”